CWA Asset Management Group LLC Acquires Shares of 28,693 Jazz Pharmaceuticals plc (NASDAQ:JAZZ)

CWA Asset Management Group LLC bought a new position in Jazz Pharmaceuticals plc (NASDAQ:JAZZ) during the 3rd quarter, according to its most recent disclosure with the Securities & Exchange Commission. The fund bought 28,693 shares of the specialty pharmaceutical company’s stock, valued at approximately $3,197,000.

Other large investors have also recently made changes to their positions in the company. Capital World Investors purchased a new position in Jazz Pharmaceuticals during the 1st quarter valued at approximately $171,943,000. Swedbank AB bought a new position in shares of Jazz Pharmaceuticals during the 2nd quarter valued at approximately $106,936,000. Rubric Capital Management LP purchased a new position in shares of Jazz Pharmaceuticals in the second quarter valued at $65,812,000. Pacer Advisors Inc. increased its position in Jazz Pharmaceuticals by 40.7% in the second quarter. Pacer Advisors Inc. now owns 1,820,913 shares of the specialty pharmaceutical company’s stock worth $194,346,000 after purchasing an additional 527,187 shares during the last quarter. Finally, Baupost Group LLC MA increased its position in Jazz Pharmaceuticals by 52.8% in the second quarter. Baupost Group LLC MA now owns 1,274,248 shares of the specialty pharmaceutical company’s stock worth $136,000,000 after purchasing an additional 440,552 shares during the last quarter. 89.14% of the stock is owned by institutional investors.

Insider Buying and Selling

In other Jazz Pharmaceuticals news, CEO Bruce C. Cozadd sold 1,000 shares of Jazz Pharmaceuticals stock in a transaction on Friday, November 1st. The stock was sold at an average price of $110.84, for a total transaction of $110,840.00. Following the completion of the sale, the chief executive officer now directly owns 428,976 shares of the company’s stock, valued at $47,547,699.84. The trade was a 0.00 % decrease in their position. The sale was disclosed in a document filed with the SEC, which is available at this hyperlink. In other news, SVP Mary Elizabeth Henderson sold 1,410 shares of the stock in a transaction that occurred on Friday, September 6th. The shares were sold at an average price of $108.30, for a total transaction of $152,703.00. Following the transaction, the senior vice president now directly owns 14,531 shares in the company, valued at approximately $1,573,707.30. This trade represents a 0.00 % decrease in their ownership of the stock. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this link. Also, CEO Bruce C. Cozadd sold 1,000 shares of the business’s stock in a transaction that occurred on Friday, November 1st. The stock was sold at an average price of $110.84, for a total transaction of $110,840.00. Following the completion of the transaction, the chief executive officer now directly owns 428,976 shares of the company’s stock, valued at $47,547,699.84. This trade represents a 0.00 % decrease in their position. The disclosure for this sale can be found here. 4.20% of the stock is owned by insiders.

Wall Street Analysts Forecast Growth

A number of equities analysts have commented on the stock. JPMorgan Chase & Co. lifted their price objective on shares of Jazz Pharmaceuticals from $190.00 to $202.00 and gave the stock an “overweight” rating in a research note on Monday, August 19th. Cantor Fitzgerald reiterated an “overweight” rating and issued a $140.00 price target on shares of Jazz Pharmaceuticals in a research report on Monday, September 9th. Needham & Company LLC restated a “buy” rating and set a $207.00 price objective on shares of Jazz Pharmaceuticals in a research report on Thursday. TD Cowen dropped their target price on Jazz Pharmaceuticals from $200.00 to $195.00 and set a “buy” rating for the company in a report on Thursday. Finally, Piper Sandler decreased their price target on Jazz Pharmaceuticals from $188.00 to $166.00 and set an “overweight” rating on the stock in a report on Thursday, August 1st. Three equities research analysts have rated the stock with a hold rating, twelve have issued a buy rating and one has given a strong buy rating to the stock. According to data from MarketBeat, the company has a consensus rating of “Moderate Buy” and an average price target of $175.00.

Jazz Pharmaceuticals Stock Up 3.8 %

Shares of JAZZ opened at $123.61 on Friday. The firm has a fifty day moving average price of $110.64 and a 200-day moving average price of $109.78. The company has a current ratio of 2.37, a quick ratio of 2.02 and a debt-to-equity ratio of 1.36. The firm has a market capitalization of $7.63 billion, a P/E ratio of 17.41, a P/E/G ratio of 1.40 and a beta of 0.57. Jazz Pharmaceuticals plc has a 12-month low of $99.06 and a 12-month high of $134.17.

Jazz Pharmaceuticals (NASDAQ:JAZZ) last released its quarterly earnings data on Wednesday, November 6th. The specialty pharmaceutical company reported $5.86 earnings per share (EPS) for the quarter, beating the consensus estimate of $4.54 by $1.32. The company had revenue of $1.05 billion during the quarter, compared to analysts’ expectations of $1.04 billion. Jazz Pharmaceuticals had a net margin of 11.60% and a return on equity of 30.16%. Equities research analysts expect that Jazz Pharmaceuticals plc will post 16.02 earnings per share for the current year.

About Jazz Pharmaceuticals

Jazz Pharmaceuticals plc identifies, develops, and commercializes pharmaceutical products for unmet medical needs in the United States, Europe, and internationally. The company offers Xywav for cataplexy or excessive daytime sleepiness (EDS) with narcolepsy and idiopathic hypersomnia; Xyrem to treat cataplexy or EDS with narcolepsy; Epidiolex for seizures associated with Lennox-Gastaut and Dravet syndromes, or tuberous sclerosis complex; Zepzelca to treat metastatic small cell lung cancer, or with disease progression on or after platinum-based chemotherapy; Rylaze for acute lymphoblastic leukemia or lymphoblastic lymphoma; Enrylaze to treat acute lymphoblastic leukemia and lymphoblastic lymphoma; Defitelio to treat severe hepatic veno-occlusive disease; and Vyxeos for newly-diagnosed therapy-related acute myeloid leukemia.